Squarepoint Ops LLC Has $1.41 Million Stake in Alkermes plc $ALKS

Squarepoint Ops LLC raised its holdings in Alkermes plc (NASDAQ:ALKS) by 65.5% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 49,267 shares of the company’s stock after buying an additional 19,503 shares during the period. Squarepoint Ops LLC’s holdings in Alkermes were worth $1,410,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of the business. Norges Bank bought a new stake in Alkermes during the second quarter worth about $53,326,000. BNP Paribas Financial Markets raised its stake in shares of Alkermes by 787.2% during the 2nd quarter. BNP Paribas Financial Markets now owns 1,135,478 shares of the company’s stock worth $32,486,000 after purchasing an additional 1,007,488 shares in the last quarter. Acadian Asset Management LLC boosted its holdings in shares of Alkermes by 2,422.0% in the 1st quarter. Acadian Asset Management LLC now owns 881,827 shares of the company’s stock valued at $29,100,000 after buying an additional 846,861 shares during the last quarter. Driehaus Capital Management LLC bought a new position in shares of Alkermes in the first quarter valued at $26,179,000. Finally, Holocene Advisors LP increased its holdings in Alkermes by 31.2% during the second quarter. Holocene Advisors LP now owns 2,853,768 shares of the company’s stock worth $81,646,000 after buying an additional 679,166 shares during the last quarter. 95.21% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

ALKS has been the subject of a number of recent analyst reports. Weiss Ratings reiterated a “buy (b-)” rating on shares of Alkermes in a research note on Tuesday. Jefferies Financial Group set a $56.00 price objective on shares of Alkermes and gave the stock a “buy” rating in a research note on Tuesday, October 28th. Wall Street Zen cut shares of Alkermes from a “strong-buy” rating to a “buy” rating in a research note on Sunday, November 9th. HC Wainwright restated a “neutral” rating on shares of Alkermes in a research note on Wednesday, October 22nd. Finally, Mizuho raised their target price on Alkermes from $40.00 to $45.00 and gave the company an “outperform” rating in a report on Monday, October 27th. One analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $44.69.

Insider Activity

In other news, EVP Craig C. Hopkinson sold 9,000 shares of Alkermes stock in a transaction on Monday, November 3rd. The shares were sold at an average price of $30.38, for a total transaction of $273,420.00. Following the transaction, the executive vice president owned 69,740 shares in the company, valued at approximately $2,118,701.20. The trade was a 11.43% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders have sold a total of 25,748 shares of company stock worth $786,830 over the last ninety days. 4.40% of the stock is currently owned by company insiders.

Alkermes Stock Performance

Shares of ALKS opened at $28.45 on Friday. Alkermes plc has a 52 week low of $25.17 and a 52 week high of $36.45. The stock has a market capitalization of $4.70 billion, a price-to-earnings ratio of 14.08 and a beta of 0.49. The stock has a fifty day moving average of $29.98 and a 200-day moving average of $29.24.

Alkermes (NASDAQ:ALKS) last posted its earnings results on Tuesday, October 28th. The company reported $0.49 EPS for the quarter, beating the consensus estimate of $0.41 by $0.08. The firm had revenue of $394.19 million during the quarter, compared to the consensus estimate of $355.23 million. Alkermes had a return on equity of 21.81% and a net margin of 22.27%.The business’s quarterly revenue was up 4.3% on a year-over-year basis. During the same period last year, the company earned $0.73 earnings per share. Alkermes has set its FY 2025 guidance at 1.360-1.470 EPS. As a group, equities analysts forecast that Alkermes plc will post 1.31 EPS for the current year.

Alkermes Company Profile

Alkermes plc is a biopharmaceutical company focused on developing innovative medicines to address unmet needs in the central nervous system (CNS). The company applies its proprietary drug delivery technologies and therapeutic expertise to advance treatments for addiction, schizophrenia, bipolar I disorder and depression. Alkermes’ portfolio includes both commercial products and a pipeline of investigational therapies designed to improve patient outcomes and support long-term disease management.

Alkermes’ commercial franchise features several approved products.